1.1Larger dose volume
The ingredient is dissolved at a concentration below its measured solubility at the lowest specified storage temperature. An oral dosing syringe meters a volume equal to the target dose divided by the solution concentration.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The ingredient is dissolved at a concentration below its measured solubility at the lowest specified storage temperature. An oral dosing syringe meters a volume equal to the target dose divided by the solution concentration.
A citrate buffer holds the vehicle at a pH where a weakly basic ingredient is predominantly protonated. The formulation sets the dose concentration below the measured saturation limit in the finished vehicle.
An insulated shipper uses a battery-powered heater and a thermostat to maintain a payload temperature of 5 to 8 °C. An independent logger records the payload temperature throughout transit for receipt verification.
A unit-dose kit holds the dry ingredient in a sealed vial and the aqueous vehicle in a separate ampoule. The full vehicle volume is transferred into the vial and shaken to form a suspension immediately before the full dose is withdrawn.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A reservoir holds micronized titanium dioxide in water with a polyacrylate dispersant. The titanium dioxide particles have an upper size limit of 10 μm, and the total mineral loading exceeds its aqueous saturation concentration. A metering pump injects the suspension into a recirculating test flume, where a downstream turbidity sensor tracks mixing. After freeze–thaw cycling, the redispersed stock produces the specified turbidity at a fixed dilution and meets the particle size limit.
A sealed vessel holds ethyl acetate and micronized calcium carbonate with an upper particle size limit of 10 μm. The calcium carbonate loading exceeds its equilibrium solubility in ethyl acetate, and an ester-compatible polymeric dispersant adsorbs onto the particles. The vessel retains headspace for expansion during cooling. Freeze–thaw verification uses temperature endpoints that solidify and remelt the ethyl acetate and checks particle size after redispersion.
Two classified fractions of the same low-solubility solid contain particles between 2 and 4 μm and between 7 and 10 μm, respectively. The fractions contribute 30% and 70% of the solid mass, respectively, and the total ingredient loading is five times its saturation concentration in the liquid phase at 20 °C. The liquid phase wets each fraction separately before the two slurries enter a common mixing vessel. After the prescribed freeze–thaw cycle, particle sizing checks the upper limit and samples from the top and bottom check solids uniformity after redispersion.
Heat-sealed flexible pouches hold 25 mL each of a suspension with particles up to 10 μm and a total ingredient loading above saturation. Spaced plates hold the filled portion of each pouch at a thickness of 4 mm and contact both broad faces during freezing and thawing. A thermocouple at the center of a reference pouch confirms when the contents reach each prescribed temperature endpoint. After thawing, ten end-over-end inversions redistribute the solids before particle sizing and concentration measurements.
A jacketed hold tank contains a suspension with particles up to 10 μm and a total ingredient loading above saturation. A low-shear pump draws from the bottom of the tank and returns flow below the liquid surface, while a branch supplies a positive-displacement filling head. The loop circulates throughout filling, and the head meters individual doses into sealed cartridges. After freeze–thaw cycling, recovered cartridge contents are checked for particle size and delivered mass after redispersion.
A recirculating bead mill processes a slurry whose total ingredient loading exceeds its saturation concentration in the continuous phase. A side-stream laser diffraction cell measures the particle size distribution, and a temperature probe monitors the mill outlet. A controller adjusts the cooling jacket and stops milling when the measured upper particle size meets the 10 μm limit. A separate measurement after freeze–thaw cycling checks whether the redispersed batch still meets that limit.
An excess of the crystalline ingredient is equilibrated with the complete aqueous vehicle at 25 °C, and a filtered sample gives a dissolved concentration of 0.2 mg/mL. The suspension contains 2 mg/mL total ingredient, with approximately 1.8 mg/mL remaining as dispersed solid at equilibrium.
Aqueous glycerol reduces ice formation, and sodium carboxymethylcellulose increases the viscosity of the liquid phase. After the specified freeze and thaw cycles, the batch passes when it meets the preset limits for particle size and redispersion.
Poloxamer adsorbs to hydrophobic crystal surfaces and provides a steric barrier as ice formation concentrates particles in the unfrozen liquid. After the specified cycles, the batch passes when it meets preset criteria for particle size, redispersion and dose uniformity.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
A pharmaceutical formulation according to any of the preceding embodiments wherein the pharmaceutical formulation comprises the at least one pharmaceutically acceptable salt of rotigotine in an amount of less than 100% of the amount necessary to achieve saturation. 14.B · US 2012/0101146 A1 · ¶ 125
The current invention sets forth a method to make durable non-vitrified fly ash masonry units that can pass 50 cycles of freeze/thaw.A · US 2007/0000412 A1 · ¶ 39
An empty cell means only that no passage was reproduced there.
Consequently, by using the non-vitrified fly ash bricks instead of the vitrified (fired) clay bricks, the fossil fuel used in vitrifying clay bricks and the air pollutant caused by burning the fossil fuel are both avoided, making the non-vitrified fly ash brick technology both energy-efficient and pollution-free.A · US 2007/0000412 A1 · ¶ 3
A more effective method to improve the freeze/thaw resistance of the fly ash brick was needed.A · US 2007/0000412 A1 · ¶ 6
The present invention relates to new salts of 6-(propyl-(2-thiophen-2-ylethyl)amino)tetralin-1-ol (rotigotine), their use as a medicament, for example for the treatment of Parkinson Disease, RLS, fybromyalgia and/or depression, in particular through electromotive administration.B · US 2012/0101146 A1 · ¶ 1
The present invention provides pharmaceutical formulations suitable for iontophoresis that provide enhanced iontophoretic delivery of rotigotine to at least one target tissue.B · US 2012/0101146 A1 · ¶ 3
patent.fyi, US 2026/0355110 A1, claim 1, first published 2026-11-19T07:53:10-05:00, https://patent.fyi/US20260355110/, SHA-256 07cfad39edf3e2876abee4c763dc5e06c8d1594758e549a8738fa45a5e038c1e